🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for KRAS G12D Mutations

A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation NCT07784374Phase 21 site📍 Shanghai Genfleet Therapeutics (Shanghai) Inc. · Tests: GFH375, GFH276, GFS202A A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation. NCT07456046Phase 19 sites📍 New Haven📍 Houston📍 San Antonio D3 Bio (Wuxi) Co., Ltd · Tests: D3S-003 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations NCT07610798Phase 1, Phase 21 site📍 Guangzhou Shenzhen Ionova Life Sciences Co., Ltd. · Tests: INV-8989 A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation NCT07535112Phase 121 sites📍 Phoenix📍 Duarte📍 San Diego Bayer · Tests: BAY 3771249, Cetuximab Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors NCT06218914Phase 118 sites📍 Duarte📍 Los Angeles📍 Newport Beach AstraZeneca · Tests: NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation NCT07259590Phase 1, Phase 24 sites📍 Beijing📍 Guangzhou📍 Zhengzhou Genfleet Therapeutics (Shanghai) Inc. · Tests: GFH375, GFH375 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC NCT07777822Phase 31 site📍 Plantation Revolution Medicines, Inc. · Tests: zoldonrasib, Placebo, pembrolizumab, pemetrexed + cisplatin /carboplatin A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors NCT07094204Phase 122 sites📍 Santa Monica📍 Atlanta📍 Jefferson Astellas Pharma Inc · Tests: ASP5834, panitumumab A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation NCT06179160Phase 134 sites📍 Phoenix📍 Palo Alto📍 Santa Monica Incyte Corporation · Tests: INCB161734, Cetuximab, Retifanlimab, GEMNabP, mFOLFIRINOX Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) NCT07621718Phase 319 sites📍 Phoenix📍 Tucson📍 New Haven Revolution Medicines, Inc. · Tests: Zoldonrasib, Placebo, Oxaliplatin, Leucovorin (Calcium Folinate), 5-Fluorouracil Imatinib and Trametinib for KRAS-mutated Solid Tumor NCT06962254Phase 11 site📍 Taichung China Medical University Hospital · Tests: Imatinib, Trametinib Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma NCT07805954Phase 35 sites📍 Phoenix📍 Scottsdale📍 Jacksonville Revolution Medicines, Inc. · Tests: daraxonrasib, gemcitabine, nab-paclitaxel, zoldonrasib HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer NCT07232875Phase 31 site📍 Shanghai Jiangsu HengRui Medicine Co., Ltd. · Tests: HRS-4642 + AG, HRS-4642 placebo + AG JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration NCT06973564Phase 1, Phase 24 sites📍 Rochester📍 St Louis📍 Cleveland Jacobio Pharmaceuticals Co., Ltd. · Tests: JAB-23E73, Cetuximab A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors NCT06403735Phase 15 sites📍 Guangzhou📍 Harbin📍 Nanchang Qilu Pharmaceutical Co., Ltd. · Tests: QLC1101 Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations NCT07134998Phase 12 sites📍 Shanghai📍 Chengdu Jiangsu HengRui Medicine Co., Ltd. · Tests: HRS-6093 A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration NCT06959615Phase 1, Phase 232 sites📍 Hefei📍 Beijing📍 Beijing Jacobio Pharmaceuticals Co., Ltd. · Tests: JAB-23E73, JAB-23E73 A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma NCT07522073Phase 3230 sites📍 Birmingham📍 Anchorage📍 Chandler Incyte Corporation · Tests: INCB161734, Placebo, Investigator's choice of chemotherapy A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors NCT07020221Phase 1, Phase 220 sites📍 Los Angeles📍 Baltimore📍 Boston Verastem, Inc. · Tests: VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab, Gemcitabine + Nab-paclitaxel, Pembrolizumab HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation NCT07240766Phase 22 sites📍 Hangzhou📍 Hangzhou Zhejiang University · Tests: HRS-4642+AG+Nimotuzumab A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation NCT07566052Phase 323 sites📍 Glendale📍 Los Angeles📍 San Francisco Astellas Pharma Global Development, Inc. · Tests: Setidegrasib, Docetaxel A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies NCT07207707Phase 113 sites📍 La Jolla📍 Los Angeles📍 Denver Kumquat Biosciences Inc. · Tests: KQB548 A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations NCT06500676Phase 1, Phase 220 sites📍 Hefei📍 Beijing📍 Beijing Genfleet Therapeutics (Shanghai) Inc. · Tests: GFH375 QTX3034 in Patients With KRAS G12D Mutation NCT06227377Phase 114 sites📍 Los Angeles📍 Denver📍 New Haven Quanta Therapeutics · Tests: QTX3034, Cetuximab Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies NCT05786924Phase 1, Phase 249 sites📍 Gilbert📍 Los Angeles📍 Los Angeles Institut de Recherches Internationales Servier · Tests: S241656, FOLFOX6/FOLFOX7, FOLFIRI, Cetuximab, Panitumumab HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients NCT06770452Phase 22 sites📍 Hangzhou📍 Hangzhou Zhejiang University · Tests: HRS-4642, Nimotuzumab, gemcitabine + nab-paclitaxel A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer NCT07438106Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: HRS-4642 Injection A Study of ASP3082 in Adults With Advanced Solid Tumors NCT05382559Phase 168 sites📍 Duarte📍 Santa Monica📍 Denver Astellas Pharma Inc · Tests: Setidegrasib, Cetuximab, Leucovorin, Oxaliplatin, Fluorouracil Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC NCT06162221Phase 1, Phase 298 sites📍 Gilbert📍 Duarte📍 Irvine Revolution Medicines, Inc. · Tests: RMC-6291, RMC-6236, Pembrolizumab, Cisplatin, Carboplatin To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. NCT07303465Phase 22 sites📍 Nanjing📍 Shanghai Ranok Therapeutics (Hangzhou) Co., Ltd. · Tests: RNK08954
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy